<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627248</url>
  </required_header>
  <id_info>
    <org_study_id>HECT002</org_study_id>
    <nct_id>NCT02627248</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE:

      Huaier (Trametes robiniophila Murr) is a traditional Chinese medicine, which has been widely
      used in China for many years. The investigators have found that Huaier could exert
      synergistic effects with Epirubicin, Cyclophosphamide, and Paclitaxel on breast cancer cells.
      It is not yet known whether combination chemotherapy is more effective when given together
      with Huaier in the neoadjuvant setting .

      PURPOSE:

      To evaluate the effects of treatment with Huaier Granule in managing locally advanced breast
      cancers with synergistic action of the neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response (pCR)</measure>
    <time_frame>one month after operation</time_frame>
    <description>A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) was allowed).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Complete Response (cCR)</measure>
    <time_frame>one month after the neoadjuvant chemotherapy</time_frame>
    <description>A cCR was defined as achieving either a Complete Response (CR) or a Partial Response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>DFS was defined as the date of definitive surgery until the date of recurrence, metastasis, appearance of a second primary tumor, or death from any cause, whichever occurs first, assessed up to 10 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>OS was defined as the date of definitive surgery until the date of death from any cause, assessed up to 10 years.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Heterogeneity of the HR status in core biopsy and the surgical specimen</measure>
    <time_frame>one month after operation</time_frame>
    <description>Evaluation of the HR and HER2 status with immunohistochemical (IHC) staining.</description>
  </other_outcome>
  <other_outcome>
    <measure>Heterogeneity of the HER2 status in core biopsy and the surgical specimen</measure>
    <time_frame>one month after operation</time_frame>
    <description>Evaluation of the HR and HER2 status with immunohistochemical (IHC) staining.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum immunomodulating cytokines</measure>
    <time_frame>up to 1 years</time_frame>
    <description>Assessment of the change in serum immunomodulating cytokines by Bio-Plex Pro Assays.</description>
  </other_outcome>
  <other_outcome>
    <measure>The effects of Huaier Granule on adverse events of neoadjuvant chemotherapy</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The adverse events were evaluated with Common Terminology Criteria for Adverse Events (CTCAE) v4.0.</description>
  </other_outcome>
  <other_outcome>
    <measure>The effects of Huaier Granule on sleep quality of patients</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The sleep quality was evaluated with self reported VAS scale (0-10).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel, Epirubicin and Cyclophosphamide (TEC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel, Epirubicin and Cyclophosphamide + Huaier (TEC+HE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epirubicin and Docetaxel (ET)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epirubicin and Docetaxel+Huaier (ET+HE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huaier Granule</intervention_name>
    <description>20g tid, orally</description>
    <arm_group_label>Docetaxel, Epirubicin and Cyclophosphamide + Huaier (TEC+HE)</arm_group_label>
    <arm_group_label>Epirubicin and Docetaxel+Huaier (ET+HE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>70 mg/m² ivdrip, d1 for both TEC and ET regimes</description>
    <arm_group_label>Docetaxel, Epirubicin and Cyclophosphamide (TEC)</arm_group_label>
    <arm_group_label>Docetaxel, Epirubicin and Cyclophosphamide + Huaier (TEC+HE)</arm_group_label>
    <arm_group_label>Epirubicin and Docetaxel (ET)</arm_group_label>
    <arm_group_label>Epirubicin and Docetaxel+Huaier (ET+HE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m² ivdrip, d2 for both TEC and ET regimes</description>
    <arm_group_label>Docetaxel, Epirubicin and Cyclophosphamide (TEC)</arm_group_label>
    <arm_group_label>Docetaxel, Epirubicin and Cyclophosphamide + Huaier (TEC+HE)</arm_group_label>
    <arm_group_label>Epirubicin and Docetaxel (ET)</arm_group_label>
    <arm_group_label>Epirubicin and Docetaxel+Huaier (ET+HE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600 mg/m² ivdrip, d2 for TEC regimes</description>
    <arm_group_label>Docetaxel, Epirubicin and Cyclophosphamide (TEC)</arm_group_label>
    <arm_group_label>Docetaxel, Epirubicin and Cyclophosphamide + Huaier (TEC+HE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

               -  Age: ≥ 18, female;

               -  Breast cancer (TNM II, III, IV) larger than 2cm in maximal diameter able to
                  benefit from neoadjuvant chemotherapy;

               -  Ductal or lobular histological type of the breast tumor;

               -  The diagnosis and breast cancer has been confirmed by pathological examination;

               -  The liver and kidney function satisfies the following conditions within 3 days
                  after surgery (excluding day 3): aspartate aminotransferase (AST),
                  glutamic-oxalacetic transaminase (ALT) &lt; 2 upper limit of normal (ULN), total
                  bilirubin ≤ 1.5 ULN, serum creatinine &lt; 1.5 ULN;

               -  Other laboratory tests meet the following requirements within 3 days after
                  surgery (excluding day 3): Hb ≥ 90g/l, platelet count ≥ 100×109/L, absolute
                  neutrophil count &gt; 1.5×109/L;

               -  The expected survival time ≥ 8 months;

               -  The subjects volunteer to sign the informed consent.

          -  Exclusion Criteria:

               -  Breast cancers of rare histological type (other than ductal and lobular);

               -  Noninvasive cancer;

               -  Presence of organ, bone, or skin metastases;

               -  Pregnant or lactating women;

               -  Those with active bleeding due to various reasons;

               -  Those with HIV infection or AIDS-associated diseases;

               -  Those with severe acute and chronic diseases;

               -  Those with severe diabetes;

               -  Those with serious infectious diseases;

               -  Those who can not take drugs by oral route;

               -  Drug abusers or those with psychological or mental diseases that may interfere
                  with study compliance;

               -  Conditions that are considered not suitable for this study investigators
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Qilu hospital of Shandong University</name>
      <address>
        <city>Ji'nan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qifeng Yang, Professor</last_name>
      <phone>+86 18560085168</phone>
    </contact>
    <contact_backup>
      <last_name>Ning Zhang, Resident</last_name>
      <phone>+86 18560085950</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang X, Qi W, Li Y, Zhang N, Dong L, Sun M, Cun J, Zhang Y, Lv S, Yang Q. Huaier Extract Induces Autophagic Cell Death by Inhibiting the mTOR/S6K Pathway in Breast Cancer Cells. PLoS One. 2015 Jul 2;10(7):e0131771. doi: 10.1371/journal.pone.0131771. eCollection 2015.</citation>
    <PMID>26134510</PMID>
  </reference>
  <reference>
    <citation>Song X, Li Y, Zhang H, Yang Q. The anticancer effect of Huaier (Review). Oncol Rep. 2015 Jul;34(1):12-21. doi: 10.3892/or.2015.3950. Epub 2015 May 5. Review.</citation>
    <PMID>25955759</PMID>
  </reference>
  <reference>
    <citation>Kong X, Ding X, Yang Q. Identification of multi-target effects of Huaier aqueous extract via microarray profiling in triple-negative breast cancer cells. Int J Oncol. 2015 May;46(5):2047-56. doi: 10.3892/ijo.2015.2932. Epub 2015 Mar 17.</citation>
    <PMID>25826742</PMID>
  </reference>
  <reference>
    <citation>Wang X, Zhang N, Huo Q, Sun M, Dong L, Zhang Y, Xu G, Yang Q. Huaier aqueous extract inhibits stem-like characteristics of MCF7 breast cancer cells via inactivation of hedgehog pathway. Tumour Biol. 2014 Nov;35(11):10805-13. doi: 10.1007/s13277-014-2390-2. Epub 2014 Jul 31.</citation>
    <PMID>25077927</PMID>
  </reference>
  <reference>
    <citation>Wang X, Zhang N, Huo Q, Sun M, Lv S, Yang Q. Huaier aqueous extract suppresses human breast cancer cell proliferation through inhibition of estrogen receptor α signaling. Int J Oncol. 2013 Jul;43(1):321-8. doi: 10.3892/ijo.2013.1947. Epub 2013 May 20.</citation>
    <PMID>23686317</PMID>
  </reference>
  <reference>
    <citation>Wang X, Zhang N, Huo Q, Yang Q. Anti-angiogenic and antitumor activities of Huaier aqueous extract. Oncol Rep. 2012 Oct;28(4):1167-75. doi: 10.3892/or.2012.1961. Epub 2012 Aug 8.</citation>
    <PMID>22895629</PMID>
  </reference>
  <reference>
    <citation>Zhang N, Kong X, Yan S, Yuan C, Yang Q. Huaier aqueous extract inhibits proliferation of breast cancer cells by inducing apoptosis. Cancer Sci. 2010 Nov;101(11):2375-83. doi: 10.1111/j.1349-7006.2010.01680.x.</citation>
    <PMID>20718753</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Qifeng Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

